SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating geopolitical tensions in the Middle East, including drone strikes on a major Saudi oil refinery and fears of a Strait of Hormuz disruption, are driving conversation around Indonesia Energy Corp. The community highlights the stock's low float and potential for a short squeeze, recalling its significant moves during prior global energy market volatility.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending following a trading halt prompted by its acquisition of key BrewDog assets and a new U.S. licensing deal with Carlsberg, igniting investor debate. While some hail these beverage sector moves as strategic expansion ahead of potential cannabis rescheduling, many criticize management's past acquisitions and express concern over potential dilution.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending amid significant volatility, recently impacted by an earnings miss and a government contract renegotiation, which some in the community view as an overreaction. Nevertheless, sustained discussions highlight AVAV as a crucial drone technology leader, positioned to benefit from escalating global defense spending and bolstered by recent positive analyst coverage.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings (RCAT) is trending amid heightened Middle East tensions and reports of increased drone warfare, fueling speculation about rising demand for its defense drone solutions. The community is actively discussing the stock's potential for defense contracts, including its involvement in the Drone Dominance Gauntlet, alongside ongoing debates about its revenue trajectory and susceptibility to short squeezes.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is a top trending stock as escalating Middle East tensions, including reported closures of the Strait of Hormuz and attacks on major oil and LNG facilities, ignite fervent community discussion. Traders are sharply divided on whether these supply disruptions will lead to a sustained energy price rally, significantly benefiting XOM, or if the initial surge will quickly fade.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid intensifying interest in optical interconnects following major industry investments, with the community highly anticipating its disruptive wafer-scale technology to be pivotal for next-gen AI data centers and expecting imminent partnership announcements from 'even bigger' players.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending amid strong earnings driven by surging LNG volumes and strategic contract signings, fueling community discussion around its significant spot market exposure and growth potential. The broader LNG sector, including Venture Global, is also in focus as rising global natural gas prices and heightened geopolitical tensions in key shipping routes underscore the critical demand for diversified energy supply.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending after announcing positive Phase 3 SOL-1 trial results for AXPAXLI in wet AMD, demonstrating superiority over Eylea and offering a significantly reduced treatment burden, which the community sees as a potential "game-changer." Despite a market sell-off, investors are actively discussing high analyst price targets and persistent acquisition rumors from Sanofi, anticipating further upside as detailed data is presented at upcoming conferences and a regulatory filing approaches.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp is surging amidst escalating Middle East tensions and reported attacks on oil facilities, sparking concerns over crude supply disruptions. The community is actively discussing the stock's low float and high short interest, fueling speculation for a significant short squeeze within the broader rallying oil and gas sector.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is currently trending as heightened geopolitical tensions and conflict in the Middle East drive significant interest in the defense sector. The community is actively discussing its position as a key beneficiary of increased defense spending, despite some debate regarding the sustainability of its recent sharp climb.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Merck & Co., Inc. $MRK Position Lifted by Kingsview Wealth Management LLC

Kingsview Wealth Management LLC raised its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 25.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 217,170...

Elo Mutual Pension Insurance Co Has $24.19 Million Stake in Merck & Co., Inc. $MRK

Elo Mutual Pension Insurance Co raised its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 14.2% during the 3rd quarter, according to the company in its most recent 13F filing...

Fisher Asset Management LLC Sells 945,571 Shares of Merck & Co., Inc. $MRK

Fisher Asset Management LLC decreased its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 3.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange...

Davis R M Inc. Lowers Stake in Merck & Co., Inc. $MRK

Davis R M Inc. lessened its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 32.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The...

Bahl & Gaynor Inc. Sells 1,406,091 Shares of Merck & Co., Inc. $MRK

Bahl & Gaynor Inc. lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 57.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange...

<ul class="summary-bullets"><li>The company's 2025 outlook shows EBIT loss narrowing to $256.03 million from $344.18 million a year ago.</li><li>Anktiva commercialization is driving traction, with 2025 net product revenue reaching $113 million, up 700% from the previous year.</li><li>ImmunityBio's Phase 2 Quilt 2.005 data shows higher cancer-free rates and a potential BLA filing expected by Q4.</li></ul>Shares of ImmunityBio, Inc. (IBRX) jumped 1% in overnight trading Sunday as investors positioned ahead of Tuesday’s earnings, with fresh weekend buzz around Anktiva following founder Patrick Soon-Shiong’s media appearances.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped over 2% on Friday to $0.78 and added another 5% in after-hours trading.&nbsp;<h2 class="st-heading-2">Earnings Expectations Take Center Stage</h2>ImmunityBio is set to report its full-year 2025 earnings on Tuesday, with expectations building that losses may narrow as the company scales commercialization of Anktiva, its lead immunotherapy.Fiscal AI estimates for 2025 show an improvement across all metrics. Revenue is projected to rise to $113.29 million from $14.75 million in 2024, while earnings before interest and taxes (EBIT)&nbsp;are expected to narrow to a loss of $256.03 million from $344.18 million a year ago. Loss per share is forecast to improve to $0.38 from $0.59 in 2024.The company has already indicated strong commercial traction&nbsp;for Anktiva, recording $113 million in net product revenue for the drug in 2025, up 700% from the prior year, while fourth-quarter (Q4) revenue rose 431% to $38.3 million, topping Wall Street estimates of $37.8 million.Despite higher research spending pushing Q4 net loss to $61.9 million from $59.2 million, full-year net loss attributable to common shareholders improved to $351.4 million from a loss of $413.6 million in 2024.<h2 class="st-heading-2">Founder Highlights Anktiva On National TV</h2>Over the weekend, founder and executive chairman Patrick Soon-Shiong amplified the scientific importance of Anktiva through a series of national&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-retail-frenzy-founder-prime-time-tv-blitz-retail-saudi-funding-trump-tailwinds/cZTc3BORIRN">media appearances</a>, including an interview with Fox News Chief Political Anchor Bret Baier and participation in a live discussion with Christopher Cuomo on NewsNation.Reflecting on conversations aired during a segment focused on cancer research and treatment, Soon-Shiong highlighted&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2028173238338204093">on X</a> the importance of IL-15, the biological foundation of Anktiva, noting its ability to stimulate T cells, NK cells and memory T cells, which supports durable immune responses across multiple tumor types.Soon-Shiong also pointed to remarks from U.S. Food and Drug Administration (FDA) authorities that a validated mechanism of action can support additional indications, and highlighted the agency’s “plausible mechanism of action” pathway as a means to accelerate access to therapies such as IL-15. He added that results from the company’s Quilt trials in lung, breast, and pancreatic cancers showed that IL-15 has the potential to generate long-term immune memory.The founder also drew attention to combination approaches involving Anktiva and Merck’s Keytruda. He said checkpoint inhibitors such as Merck’s Keytruda work by removing the “brakes” on immune cells, while Anktiva helps grow and strengthen those immune cells. He said the combination could help patients respond if their cancer stops reacting to earlier immunotherapy.<h2 class="st-heading-2">Trial Progress Adds Momentum</h2>ImmunityBio recently completed enrollment ahead of schedule in its Phase 2 Quilt 2.005 trial evaluating Anktiva combined with BCG in patients with early-stage bladder cancer who had not previously received standard BCG therapy.The study enrolled 366 patients and an early FDA-requested review indicated improved outcomes with the combination. After six months, 85% of patients receiving Anktiva with BCG remained cancer-free compared with 57% treated with BCG alone. At nine months, 84% of patients on the combination showed no recurrence, compared with 52% on standard therapy.The company expects to submit a biologics license application for the regimen by the fourth quarter of 2026. Anktiva is already approved in combination with BCG for bladder cancer in the U.S. and has also received authorizations in the UK, Europe and Saudi Arabia. Saudi regulators recently granted accelerated approval for the therapy in combination with a checkpoint inhibitor in metastatic non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX shifted from ‘extremely bullish’ to ‘bullish’ amid a 65% decline in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_3d2d4b49a6.webp" alt="ibrx ss.png" width="975" height="143"><figcaption>IBRX sentiment and message volume as of March 2 | Source: Stocktwits</figcaption></figure>One user noted that Keytruda currently generates more than $30 billion in annual sales and is set to face patent expiration in 2028, describing Anktiva as a “better” product that could benefit from that shift. They urged traders to “buy and hold” the stock.<stembedurl>https://stocktwits.com/Johann1011/message/646276968</stembedurl>Another user said, “I look forward to tomorrow's trading day. Things look promising for IBRX!!”<stembedurl>https://stocktwits.com/BullriderNkg/message/646274508</stembedurl>IBRX stock has skyrocketed nearly 400% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong announces newest initiatives for Cancer MoonShot 2020 at Hyatt Regency Boston on October 26, 2016. (Photo by Darren McCollester/Getty Images for NantHealth, Inc.)

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

Equity

River Wealth Advisors LLC Boosts Stock Position in Merck & Co., Inc. $MRK

River Wealth Advisors LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 24.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and...

Merck & Co., Inc. $MRK Shares Bought by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.3% during the third quarter, according to the company in its most recent disclosure with...

Quantbot Technologies LP Increases Stock Position in Merck & Co., Inc. $MRK

Quantbot Technologies LP boosted its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 125.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRK News

MRKMerck & Co Inc